Subject(s)
Alzheimer Disease/etiology , Amyloid beta-Protein Precursor/metabolism , Nerve Tissue Proteins/physiology , Nuclear Proteins/physiology , Amino Acid Sequence , Animals , Binding Sites , Cytoplasm , Humans , Ligands , Molecular Sequence Data , Nerve Tissue Proteins/metabolism , Nuclear Proteins/metabolism , Phenotype , Transcription, GeneticABSTRACT
The WW domain is a globular protein domain that is involved in mediating protein-protein interaction and that ultimately participates in various intracellular signaling events. The domain binds to polyproline ligands containing the xPPxY consensus (where x signifies any amino acid, P is proline and Y is tyrosine). One of the first WW domain-ligand links that was characterized in vitro was the WW domain of Yes-Associated Protein (YAP) and its WBP-1 ligand. To further characterize this molecular interaction, we used two independent approaches, both of which focused on the mutational analysis of the WBP-1 ligand. We screened repertoires of synthetic decamer peptides containing the xPPxY core of WBP-1 in which all ten positions were sequentially replaced with the remaining amino acids. In addition, we screened decamer repertoires with all permutations of the amino acids which individually increased the binding to the WW domain of YAP, as compared to the wild type. In a parallel approach, we used a phage-displayed combinatorial peptide library biased for the presence of two consecutive prolines to study ligand preferences for the WW domain of YAP. Interestingly, these two lines of investigation converged and yielded the core sequence PPPPYP, which is preferred by the YAP-WW domain. This sequence was found within the p53 (tumor suppressor) binding protein-2, a probable cognate or alternative ligand interacting with YAP.
Subject(s)
Adaptor Proteins, Signal Transducing , Carrier Proteins/metabolism , Peptides/metabolism , Phosphoproteins/metabolism , Protein Structure, Tertiary , Amino Acid Sequence , Animals , Apoptosis Regulatory Proteins , Bacteriophages/chemistry , Bacteriophages/genetics , Bacteriophages/metabolism , Carrier Proteins/chemistry , Cell Cycle Proteins , Computational Biology , Humans , Intracellular Signaling Peptides and Proteins , Ligands , Mice , Molecular Sequence Data , Mutagenesis , Peptide Library , Phosphoproteins/chemistry , Protein Binding , Transcription Factors , YAP-Signaling ProteinsABSTRACT
The neural protein FE65 contains two types of protein-protein interaction modules: one WW binding domain and two phosphotyrosine binding domains. The carboxyl-terminal phosphotyrosine binding domain of FE65 interacts in vivo with the beta-amyloid precursor protein, which is implicated in Alzheimer disease. To understand the function of this adapter protein, we identified binding partners for the FE65 WW domain. Proline-rich sequences sharing a proline-proline-leucine-proline core motif were recovered by screening expression libraries for ligands of the FE65 WW domain. Five proteins of molecular masses 60, 75, 80, 140, and 200 kDa could be purified from mouse brain lysates by affinity to the FE65 WW domain. We identified two of these five proteins as the 80- and 140-kDa isoforms encoded by Mena, the mammalian homolog of the Drosophila Enabled gene. Using the SPOTs technique of peptide synthesis, we identified the sequences in Mena that interact with the FE65 WW domain and found that they contain the signature proline-proline-leucine-proline motif. Finally, we demonstrated that Mena binds to FE65 in vivo by coimmunoprecipitation assay from COS cell extracts. The specificity of the Mena-FE65 WW domain association was confirmed by competition assays. Further characterization of the FE65-Mena complex may identify a physiological role for these proteins in beta-amyloid precursor protein biogenesis and may help in understanding the mechanism of molecular changes that underlie Alzheimer disease.
